⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5954790 | 0.95 | — | — | |
| SCHEMBL9083312 | 0.85 | PDE3A (0.39) | — | |
| SCHEMBL5034927 | 0.84 | ABL1 (0.37) | — | |
| SCHEMBL1706308 | 0.81 | RNASE1 (0.39) | — | |
| SCHEMBL7908351 | 0.80 | TK2 (0.35) | — | |
| SCHEMBL6065319 | 0.79 | LMNA (0.32) | — | |
| SCHEMBL10381694 | 0.78 | ABL1 (0.38) | — | |
| SCHEMBL8008250 | 0.77 | CA1 (0.33) | — | |
| SCHEMBL6756344 | 0.76 | RNASE1 (0.37) | — | |
| SCHEMBL3810729 | 0.76 | HPGD (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3494221-A1 | NATURAL CRYPTIC EXON REMOVAL BY PAIRS OF ANTISENSE OLIGONUCLEOTIDES | Erasmus University Medical Center Rotterdam (NL) | 2019-06-12 | — | — | EP | disclosed |
| WO-2018026284-A1 | NATURAL CRYPTIC EXON REMOVAL BY PAIRS OF ANTISENSE OLIGONUCLEOTIDES | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (ERASMUS MC) (NL) | 2018-02-08 | — | — | WO | disclosed |
| EP-3155100-A1 | ANTISENSE OLIGONUCLEOTIDES USEFUL IN TREATMENT OF POMPE DISEASE | Erasmus University Medical Center Rotterdam (NL) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015190922-A1 | ANTISENSE OLIGONUCLEOTIDES USEFUL IN TREATMENT OF POMPE DISEASE | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2015-12-17 | — | — | WO | disclosed |
| EP-1560840-A4 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | ISIS PHARMACEUTICALS INC (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1560840-A2 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | Isis Pharmaceuticals, Inc. (US) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004044136-A2 | COMPOSITIONS COMPRISING ALTERNATING 2’-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004044131-A2 | CROSS-LINKED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |